◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › O › OCS

Oculis Holding AG (OCS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-11

Oculis Holding AG (OCS) operates in the Biotechnology industry and is headquartered in Zug, Switzerland with about 60 employees. Its market capitalization is roughly $628 million. In the fiscal year ended 2025-12-31, OCS reported CHF 0M in revenue and (CHF 99M) in net income.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.

Interactive charts & full statements → Open the OCS valuation workbench →

OCS Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CHF 0M	CHF 0M	CHF 0M	CHF 0M
Operating Income (EBIT)	(CHF 82M)	(CHF 73M)	(CHF 46M)	(CHF 32M)
Net Income	(CHF 99M)	(CHF 86M)	(CHF 89M)	(CHF 39M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2024-12-31
Total Revenue	CHF 0M	CHF 0M	CHF 0M	CHF 0M	CHF 0M	—
Operating Income (EBIT)	(CHF 24M)	(CHF 22M)	(CHF 21M)	(CHF 20M)	(CHF 21M)	—
Net Income	(CHF 10M)	(CHF 29M)	(CHF 24M)	(CHF 17M)	(CHF 25M)	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	CHF 0M	CHF 0M	CHF 0M	—	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Dividends Paid	CHF 0M	CHF 0M	CHF 0M	CHF 0M	CHF 0M	—	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 236M	CHF 120M	CHF 114M	CHF 37M	—
Total Liabilities	CHF 40M	CHF 47M	CHF 21M	CHF 135M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OCS viewer.

Other Companies in Biotechnology

ALT · Altimmune, Inc. — $640 million
2496 · Wuhan YZY Biopharma Co., Ltd. — HK$640 million
DRUG · Bright Minds Biosciences Inc. — $638 million
CTNM · Contineum Therapeutics, Inc. — $628 million
2137 · Brii Biosciences Limited — HK$621 million
ASMB · Assembly Biosciences, Inc. — $620 million
ALLO · Allogene Therapeutics, Inc. — $608 million
1244 · 3D Medicines Inc. — HK$607 million

← OCNL All “O” companies OCSL →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.